Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide 2026-02-05T14:09:13-08:00February 4th, 2026|2026 Press Releases, Press Releases| Read more
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial 2026-03-09T18:04:28-07:00July 7th, 2025|2025 Press Releases, Press Releases| Read more
LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials 2026-03-09T18:40:09-07:00June 17th, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay 2026-03-09T18:44:44-07:00April 22nd, 2025|2025 Press Releases, Press Releases| Read more
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland 2026-03-09T18:48:48-07:00March 27th, 2025|2025 Press Releases, Press Releases| Read more
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA 2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML 2026-03-09T18:43:04-07:00May 8th, 2024|2024 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA 2025-08-26T07:35:25-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research 2025-12-19T18:08:11-08:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan 2025-12-29T12:29:29-08:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay 2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China 2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan) 2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML 2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML 2026-03-08T22:24:18-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine 2025-08-26T08:08:16-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use 2026-03-09T18:50:30-07:00September 2nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China 2021-07-22T17:27:56-07:00July 22nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System 2025-08-26T08:18:25-07:00June 24th, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China 2026-03-09T18:08:11-07:00June 3rd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States 2025-08-26T08:11:34-07:00May 19th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners. 2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay 2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases| Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA 2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies 2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases| Read more
